Private company

Vyant Bio, Inc.

Vyant Bio, Inc. is an American medical laboratories services company based in Rutherford.2

Last updated Oct 20, 2026.

Overview

  • IndustryServices-Medical Laboratories2
  • HeadquartersRutherford, United States2
  • Incorporated inDE3
  • Business address2370 State Route 70 West, Suite 310, Cherry Hill,, Nj 080023
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI529900PK9IZ6P1W481532
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 30288182

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-2389.2%Operating margin4
-3406.9%Net margin4
-42.0%Revenue growth, 20224
-229.0%Return on equity4
0.01×Debt to equity4
-$14.3MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development100¢$6.8M

Out of $666.0K in revenue.4 The company lost money this year.

Financial statements

Revenue567894$666.0K in 2022−98% since 2016
0$10.0M$20.0M$30.0M2016: $27.0M$27.0M20162017: $29.1M$29.1M2017+8%2018: $4.9M$4.9M2018−83%2019: $7.3M$7.3M2019+48%2020: $867.0K$867.0K2020−88%2021: $1.1M$1.1M2021+32%2022: $666.0K$666.0K2022−42%
Gross profit5678$2.4M in 2020−76% since 2016
0$5.0M$10.0M$15.0M2016: $9.9M$9.9M20162017: $11.1M$11.1M2017+11%2018: $1.8M$1.8M2018−83%2019: $3.6M$3.6M2019+96%2020: $2.4M$2.4M2020−33%
Operating income567894-$15.9M in 2022−5% since 2016
-$20.0M-$15.0M-$10.0M-$5.0M02016: -$16.7M-$16.7M20162017: -$18.6M-$18.6M2017+11%2018: -$7.7M-$7.7M2018−59%2019: -$5.7M-$5.7M2019−26%2020: -$7.6M-$7.6M2020+34%2021: -$15.7M-$15.7M2021+106%2022: -$15.9M-$15.9M2022+1%
Net income567894-$22.7M in 2022+44% since 2016
-$60.0M-$40.0M-$20.0M02016: -$15.8M-$15.8M20162017: -$20.9M-$20.9M2017+32%2018: -$20.4M-$20.4M2018−2%2019: -$6.7M-$6.7M2019−67%2020: -$8.7M-$8.7M2020+29%2021: -$40.9M-$40.9M2021+372%2022: -$22.7M-$22.7M2022−44%
Fiscal year2016201720182019202020212022
Revenue$27.0M5$29.1M6$4.9M7$7.3M8$867.0K9$1.1M4$666.0K4
Cost of revenue$17.1M5$18.1M6$3.1M7$3.7M8$3.4M8
Gross profit$9.9M5$11.1M6$1.8M7$3.6M8$2.4M8
Research and development$6.0M5$4.8M6$154.0K7$07$3.2M9$4.3M4$6.8M4
Operating expenses$16.9M4$16.6M4
Operating income-$16.7M5-$18.6M6-$7.7M7-$5.7M8-$7.6M9-$15.7M4-$15.9M4
Interest$454.0K5$2.1M6$319.0K7$1.4M8$272.0K8
Income before tax-$18.6M4-$15.8M4
Income tax$05-$2.1M6$07-$512.0K8$08
Net income-$15.8M5-$20.9M6-$20.4M7-$6.7M8-$8.7M9-$40.9M4-$22.7M4
Earnings per share-$1.0013-$9.034-$3.874
Earnings per share (diluted)-$1.0013
Shares (weighted, basic)4.5M shares45.9M shares4
Shares (weighted, diluted)4.5M shares45.9M shares4

Compare Vyant Bio, Inc. with another company

Corporate structure

Vyant Bio, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Vyant Bio, Inc.

  • FOD Capital, LLC Filed SC 13G/A on Vyant Bio, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • INTRACOASTAL CAPITAL, LLC Filed SC 13G/A on Vyant Bio, Inc., latest Feb 11, 2022
  • RENAISSANCE TECHNOLOGIES LLC Filed SC 13G/A on Vyant Bio, Inc., latest Feb 11, 2022
  • Lind Global Macro Fund LP Filed SC 13G/A on Vyant Bio, Inc., latest Feb 9, 2022
  • BIGGER CAPITAL FUND L P Filed SC 13G/A on Vyant Bio, Inc., latest Feb 7, 2022
  • Vyant Bio, Inc. Rutherford, New Jersey, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Vyant Bio, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.6M4 Dec 31, 2022$3.0M4 Dec 31, 2021+19.7%
Accumulated depreciation$2.5M4 Dec 31, 2022$2.0M4 Dec 31, 2021+25.6%
Property and equipment, net$1.1M4 Dec 31, 2022$1.0M4 Dec 31, 2021+8.4%
Operating-lease assets (leased space)$1.5M4 Dec 31, 2022$1.2M4 Jan 31, 2022+28.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$10.0M4 Dec 31, 2022$20.6M4 Dec 31, 2021−51.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$2.2M4 Dec 31, 2021$3.0M8 Dec 31, 2020−27.3%
Finite-lived intangibles, gross$9.5M4 Dec 31, 2021$08 Dec 31, 2020
Accumulated amortization$713.0K4 Dec 31, 2021$08 Dec 31, 2020
Finite-lived intangibles, net$04 Dec 31, 2022$8.8M4 Dec 31, 2021−100.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$53.0K4 Dec 31, 2022$475.0K4 Dec 31, 2021−88.8%
Raw materials$44.0K4 Dec 31, 2022$314.0K4 Dec 31, 2021−86.0%
Work in process$9.0K4 Dec 31, 2022$138.0K4 Dec 31, 2021−93.5%
Finished goods$23.0K4 Dec 31, 2021$40.0K9 Dec 31, 2020−42.5%

Leadership

Who has led Vyant Bio, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Panna Sharma2013–2017

President

  1. Panna Sharma2014
  2. Ralf Brandt2017–2021

Chief financial officer

  1. Elizabeth Czerepak2013
  2. Edward J. Sitar2014–2016
  3. Michael Glenn Miles2018–2020
201520202025
Board members and other officers (25)

Former names

  • CANCER GENETICS, INCDec 30, 2011 to Mar 31, 20213
  • CANCER GENETICS INCJan 10, 2006 to Nov 1, 20103

Timeline

  1. May 10, 20238-K Executive or director change43
  2. Apr 24, 20238-K Listing notice or transfer; Other events44
  3. Mar 24, 20238-K Ended a material agreement; Other events45
  4. Mar 22, 20238-K Listing notice or transfer46
  5. Mar 15, 20238-K Entered a material agreement47
  6. Mar 13, 20238-K Other events48
  7. Feb 3, 20238-K Exit or restructuring costs; Executive or director change; Other events49
  8. Jan 5, 20238-K Entered a material agreement50
  9. Jan 4, 20238-K Other events51
  10. Dec 19, 20228-K Bylaws or fiscal year changed52
  11. Dec 5, 20228-K Executive or director change53
  12. Nov 16, 20228-K Other events54
  13. Apr 4, 2013New chief executive Panna Sharma becomes CEO14

Calendar

When it reported results

  1. May 16, 2022Reported quarterly or annual results55
  2. Mar 1, 2022Reported quarterly or annual results56

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

111 filings to the SEC since October 2021: 2 annual reports, 4 quarterly reports, 25 major events, 43 insider forms, 6 large holders, 31 other. The latest 20:

  1. Aug 16, 2023DEF 14A EDGAR
  2. Jul 31, 2023PRE 14A EDGAR
  3. May 15, 202315-12G EDGAR
  4. May 10, 20238-K EDGAR
  5. May 4, 202325 EDGAR
  6. Apr 24, 20238-K EDGAR
  7. Mar 31, 202310-K EDGAR
  8. Mar 27, 2023EFFECT EDGAR
  9. Mar 27, 2023EFFECT EDGAR
  10. Mar 27, 2023EFFECT EDGAR
  11. Mar 27, 2023EFFECT EDGAR
  12. Mar 27, 2023EFFECT EDGAR
  13. Mar 27, 2023EFFECT EDGAR
  14. Mar 24, 20238-K EDGAR
  15. Mar 24, 2023POS AM EDGAR
  16. Mar 24, 2023POS AM EDGAR
  17. Mar 24, 2023POS AM EDGAR
  18. Mar 24, 2023POS AM EDGAR
  19. Mar 24, 2023POS AM EDGAR
  20. Mar 24, 2023POS AM EDGAR

The 111 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 7 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 18, 2022Harris Geoffrey E.DirectorSale765$1.33$1.0KForm 4
Dec 6, 2021Boehm MarcusDirectorBuy5,000$1.69$8.4KForm 4
Nov 24, 2021ROBERTS JOHN AChief Executive OfficerBuy5,000$2.02$10.1KForm 4
Nov 23, 2021LaFrence Andrew D.C.Chief Financial OfficerBuy5,000$2.00$10.0KForm 4
Nov 23, 2021LaFrence Andrew D.C.Chief Financial OfficerBuy5,000$2.00$10.0KForm 4
Nov 22, 2021Yeh Yung-PingDirectorBuy500$2.05$1.0KForm 4
Oct 28, 2021Fremeau Robert Thomas Jr.Chief Scientific OfficerBuy1,000$2.19$2.2KForm 4
Oct 27, 2021Boehm MarcusDirectorBuy5,000$2.10$10.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Vyant Bio, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARVyant Bio, Inc.1
  • CIK0001349929
  • Employer ID (EIN)04-34624751
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)8071 Services-Medical Laboratories1
  • Business address2370 State Route 70 West, Suite 310, Cherry Hill,, NJ 080021
  • Phone201.528.92001
  • Shares outstanding6,267,708 as of Mar 15, 20234
  • Public float$24.7M as of Jun 30, 20224
  • On EDGAR sinceJan 10, 20061
  • Filings702 in all: 4 (180), 8-K (162), CORRESP (37), 3 (31), 10-Q (30), S-1/A (27), 425 (21), UPLOAD (21)1
    All 46 form types

    SC 13G/A (19), 424B5 (18), EFFECT (17), SC 13G (17), 4/A (13), 10-K (10), FWP (8), DEF 14A (7), POS AM (7), S-8 (6), S-8 POS (6), 8-K/A (5), D (5), NT 10-Q (5), S-1 (5), 424B4 (4), S-3 (4), SC 13D (4), 10-Q/A (3), 424B3 (3), CERTNAS (3), PRE 14A (3), 10-K/A (2), 8-A12B (2), NT 10-K (2), REGDEX (2), SC 13D/A (2), 15-12G (1), 25 (1), 3/A (1), 8-A12G (1), ARS (1), D/A (1), DEFA14A (1), DEFR14A (1), RW (1), S-4 (1), S-4/A (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2023
    Quarterly report (10-Q) Nov 14, 2022
    Proxy statement (DEF 14A) Aug 16, 2023
    Latest 8-K (8-K) May 10, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
    SEC EDGAROther events
  49. 49
  50. 50
  51. 51
    SEC EDGAROther events
  52. 52
  53. 53
  54. 54
    SEC EDGAROther events
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61